Orchard Therapeutics Plc (NASDAQ:ORTX) reported Q4 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $7 million versus the consensus estimate of $5.31 million.
Orchard Therapeutics Plc (NASDAQ:ORTX) reported Q4 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $7 million versus the consensus estimate of $5.31 million.